Last Andrew J.

SEC source: 0001062993-22-011169 · form4.xml · derivative · entry 3

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

Underlying: Bio-Rad A Common Stock · 1,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

F4 · derivative.exercise_date: On April 29, 2019, the reporting person was granted 5,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.

F4 · derivative.expiration_date: On April 29, 2019, the reporting person was granted 5,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.

SEC source: 0001062993-22-011169 · form4.xml · nonDerivative · entry 2

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,293.1217

SEC source: 0001062993-22-011169 · form4.xml · nonDerivative · entry 1

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,764.1217

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units.

F2 · balance_after: Includes 13.3620 and 14.8416 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 09/30/2021 and 03/31/2022, respectively.

SEC source: 0001062993-21-008244 · form4.xml · derivative · entry 10

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,708

Underlying: Bio-Rad A Common Stock · 902 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

F10 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 3,610 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

F10 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 3,610 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

SEC source: 0001062993-21-008244 · form4.xml · nonDerivative · entry 6

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,735.9181

SEC source: 0001062993-21-008244 · form4.xml · nonDerivative · entry 5

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,183.9181

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units.

SEC source: 0001062993-21-008244 · form4.xml · derivative · entry 9

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Bio-Rad A Common Stock · 2,000 shares

Expires 2029-04-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The option, representing a right to purchase a total of 5,000 shares, became exercisable in five equal annual installments beginning on April 29, 2020, which was the first anniversary of the date on which the option was granted.

SEC source: 0001062993-21-008244 · form4.xml · derivative · entry 8

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,532

Underlying: Bio-Rad A Common Stock · 2,532 shares

Expires 2031-09-01

F8 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant.

SEC source: 0001062993-21-008244 · form4.xml · derivative · entry 7

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,532

Underlying: Bio-Rad A Common Stock · 2,532 shares

Expires not disclosed

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

F7 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

F7 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

SEC source: 0001062993-21-008244 · form4.xml · nonDerivative · entry 4

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,281.9181

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $814.02 to $814.11, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001062993-21-008244 · form4.xml · nonDerivative · entry 3

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,880.9181

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $812.71 to $813.34, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001062993-21-008244 · form4.xml · nonDerivative · entry 2

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,531.9181

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $811.70 to $812.69, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001062993-21-008244 · form4.xml · nonDerivative · entry 1

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,281.9181

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 13.9278 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2021.

SEC source: 0001493152-21-015449 · ownership.xml · derivative · entry 2

Last Andrew J. · CIK 0001485088 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2022-06-24

F2 · derivative.exercise_date: The Restricted Stock Units shall vest one year from the date of grant, subject to the director's continued service as a director of the Company from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.

SEC source: 0001493152-21-015449 · ownership.xml · derivative · entry 1

Last Andrew J. · CIK 0001485088 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2031-06-23

F1 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.

SEC source: 0001493152-21-014342 · ownership.xml · derivative · entry 2

Last Andrew J. · CIK 0001485088 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,993 shares

Expires 2024-02-01

SEC source: 0001493152-21-014342 · ownership.xml · nonDerivative · entry 1

Last Andrew J. · CIK 0001485088 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,170

SEC source: 0001062993-21-003968 · form4.xml · derivative · entry 3

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Bio-Rad A Common Stock · 1,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

F4 · derivative.exercise_date: On April 29, 2019, the reporting person was granted 5,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.

F4 · derivative.expiration_date: On April 29, 2019, the reporting person was granted 5,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.

SEC source: 0001062993-21-003968 · form4.xml · nonDerivative · entry 2

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,267.9903

SEC source: 0001062993-21-003968 · form4.xml · nonDerivative · entry 1

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,733.9903

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units.

F2 · balance_after: Includes 16.5639 and 14.1410 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 09/30/2020 and 03/31/2021, respectively.

SEC source: 0001493152-20-023597 · ownership.xml · nonDerivative · entry 1

Last Andrew J. · CIK 0001485088 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,177

F1 · price: The shares of the Issuer's common stock were issued to the Reporting Person for the repayment of deferred compensation in lieu of cash at a price of $2.07 per share.

SEC source: 0001812865-20-000012 · edgar.xml · derivative · entry 3

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,610

Underlying: Bio-Rad A Common Stock · 3,610 shares

Expires 2030-09-02

F4 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant.

SEC source: 0001812865-20-000012 · edgar.xml · derivative · entry 2

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,610

Underlying: Bio-Rad A Common Stock · 3,610 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

F3 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

F3 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

SEC source: 0001493152-20-011542 · ownership.xml · derivative · entry 1

Last Andrew J. · CIK 0001485088 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,000

Underlying: Common Stock · 57,000 shares

Expires not disclosed

F1 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.

F1 · derivative.expiration_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.

SEC source: 0001652252-20-000002 · edgar.xml · derivative · entry 3

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Bio-Rad A Common Stock · 1,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

F4 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning on April 29, 2020.

F4 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning on April 29, 2020.

SEC source: 0001652252-20-000002 · edgar.xml · nonDerivative · entry 2

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 679.9765

SEC source: 0001652252-20-000002 · edgar.xml · nonDerivative · entry 1

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,025.9765

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units.

F2 · balance_after: Includes 25.9765 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 3/31/2020.

SEC source: 0001209191-19-042841 · doc4.xml · derivative · entry 1

Last Andrew J. · CIK 0001485088 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2029-07-16

F1 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.

SEC source: 0001652252-19-000014 · edgar.xml · derivative · entry 2

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Bio-Rad A Common Stock · 5,000 shares

Expires 2029-04-29

F3 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant.

SEC source: 0001652252-19-000014 · edgar.xml · derivative · entry 1

Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Bio-Rad A Common Stock · 5,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

F2 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant.

F2 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant.

SEC source: 0001209191-18-049414 · doc4.xml · derivative · entry 2

Last Andrew J. · CIK 0001485088 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2028-08-29

F1 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.

SEC source: 0001493152-18-010761 · ownership.xml · derivative · entry 2

Last Andrew J. · CIK 0001485088 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,993

Underlying: Common stock · 6,993 shares

Expires 2024-02-01

F1 · price: The shares of common stock and the common stock purchase warrants reported in this Form were purchased in "units," with each unit consisting of one share of common stock and one common stock purchase warrant. The purchase price per unit was $2.86.

SEC source: 0001493152-18-010761 · ownership.xml · nonDerivative · entry 1

Last Andrew J. · CIK 0001485088 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,993

F1 · price: The shares of common stock and the common stock purchase warrants reported in this Form were purchased in "units," with each unit consisting of one share of common stock and one common stock purchase warrant. The purchase price per unit was $2.86.

SEC source: 0001225385-17-000119 · edgar.xml · nonDerivative · entry 1

Last Andrew J. · CIK 0001485088 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

F1 · price: The price reported in Column 4 is a weighted average price of shares purchased in multiple transactions. The reporting person undertakes to provide to Intrexon Corporation ("Intrexon"), any security holder of Intrexon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.

SEC source: 0001225385-17-000102 · edgar.xml · nonDerivative · entry 1

Last Andrew J. · CIK 0001485088 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

SEC source: 0001209191-17-041129 · doc4.xml · derivative · entry 2

Last Andrew J. · CIK 0001485088 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2027-06-14

F2 · derivative.exercise_date: Will become exercisable in four equal installments on September 30, 2017, December 31, 2017, March 31, 2018, and one day before the Company's next annual meeting of shareholders, based upon continued service on the board of directors from the date of grant on June 15, 2017.

SEC source: 0001209191-17-041129 · doc4.xml · derivative · entry 1

Last Andrew J. · CIK 0001485088 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,520

Underlying: Common Stock · 6,520 shares

Expires 2027-06-14

F1 · shares: Options are granted to directors annually. These options are a "transitional grant" reflecting the change in the date of the annual grant from February to the date of the annual meeting of shareholders. The options are 32.60% of the annual grant for the 119-day gap between February 16, 2017, one year from the last annual grant, and June 15, 2017, date of the full annual grant for 2017-2018.

F2 · derivative.exercise_date: Will become exercisable in four equal installments on September 30, 2017, December 31, 2017, March 31, 2018, and one day before the Company's next annual meeting of shareholders, based upon continued service on the board of directors from the date of grant on June 15, 2017.